Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1976 Dec;26(3):388-96.

Immune complexes and complement hypercatabolism in patients with leprosy

Immune complexes and complement hypercatabolism in patients with leprosy

B Bjorvatn et al. Clin Exp Immunol. 1976 Dec.

Abstract

The occurrence of immune complexes in the serum and the level of the C3 breakdown product C3d in the plasma from patients with leprosy were studied by quantitative methods and the results were compared in various forms of the disease. These studies were performed on sixty-two samples from twenty-six patients. The serum 125I-C1q binding activity was found to be increased by more than 2 s.d., as compared to the normal values, in most of the sera from patients with erythema nodosum leprosum (ENL) (80%) and uncomplicated lepromatous leprosy (82%), but also in the sera from patients with tuberculoid leprosy (58%). In vitro studies suggested that immune complexes involving mycobacterial antigens were present in leprosy sera. An increased C3d level (greater than 2s.d.) was also found in most of the plasma from patients with ENL (70%), but rarely in the plasma from patients with uncomplicated lepromatous leprosy (18%) and never in tuberculoid leprosy patients' plasma. The absence of a significant correlation between the 125I-C1q binding activity and the C3d level in leprosy patients may suggest that extravascular immune complexes are involved in the complement activation occurring in ENL. The quantitation of C3d in plasma may be of some practical interest in the early diagnosis of ENL complications of leprosy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Adv Immunol. 1973;16(0):185-264 - PubMed
    1. Clin Exp Immunol. 1972 Oct;12(2):215-23 - PubMed
    1. J Immunol. 1972 Oct;109(4):910-3 - PubMed
    1. Am J Trop Med Hyg. 1974 May;23(3):471-5 - PubMed
    1. J Clin Invest. 1974 Aug;54(2):297-309 - PubMed

LinkOut - more resources